Polymorph of Syk inhibitors
Polymorphs of a bis-mesylate salt of a compound of Formula I: or a hydrate thereof, are provided. The bis-mesylate salt may also be depicted as a compound of Formula IA: Provided herein are also compositions thereof, methods for their preparation and methods for such polymorphs.
1. A method of producing polymorph Form 3 of a monohydrate, bis-mesylate salt of a compound of Formula I:
comprising:
adding an amount of polymorph Form 3 of a monohydrate, bis-mesylate salt of a compound of Formula I seeds and a solvent to polymorph Form 7 of a hydrate, bis-mesylate salt of a compound of Formula I to form a mixture; and
producing polymorph Form 3 of a monohydrate, bis-mesylate salt of a compound of Formula I in the mixture,
wherein the polymorph Form 3 of a monohydrate, bis-mesylate salt of a compound of Formula I has an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, selected from the group consisting of A: 13.8, 16.9, 22.9, and 26.1; B: 7.7, 12.9, 17.7, and 18.1; and C: 7.7, 12.9, 13.8, 16.9, 17.7, 18.1, 22.9, and 26.1; and
wherein the polymorph Form 7 of a hydrate, bis-mesylate salt of a compound of Formula I has an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, selected from the group consisting of A: 4.9, 9.8, and 26.7; B: 15.0 and 18.0; and C: 4.9, 9.8, 15.0, 18.0, and 26.7.
2. A method of treating a cancer in a human in need thereof, comprising administering to the human a therapeutically effective amount of a monohydrate of a bis-mesylate salt of a compound of Formula I:
wherein the cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantel cell lymphoma (MCL), follicular lymphoma (FL), Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma (LPL), or marginal zone lymphoma (MZL); and
further wherein the monohydrate of the bis-mesylate salt is a polymorph characterized by an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 13.8, 16.9, 22.9, and 26.1.
3. The method of claim 2 , wherein the cancer is acute lymphocytic leukemia (ALL).
4. The method of claim 2 , wherein the cancer is acute myeloid leukemia (AML).
5. The method of claim 2 , wherein the cancer is chronic lymphocytic leukemia (CLL).
6. The method of claim 2 , wherein the cancer is small lymphocytic lymphoma (SLL).
7. The method of claim 2 , wherein the cancer is myelodysplastic syndrome (MDS).
8. The method of claim 2 , wherein the cancer is myeloproliferative disease (MPD).
9. The method of claim 2 , wherein the cancer is chronic myeloid leukemia (CML).
10. The method of claim 2 , wherein the cancer is multiple myeloma (MM).
11. The method of claim 2 , wherein the cancer is non-Hodgkin's lymphoma (NHL).
12. The method of claim 2 , wherein the cancer is mantel cell lymphoma (MCL).
13. The method of claim 2 , wherein the cancer is follicular lymphoma (FL).
14. The method of claim 2 , wherein the cancer is Waldestrom's macroglobulinemia (WM).
15. The method of claim 2 , wherein the cancer is T-cell lymphoma.
16. The method of claim 2 , wherein the cancer is B-cell lymphoma.
17. The method of claim 2 , wherein the cancer is diffuse large B-cell lymphoma (DLBCL).
18. The method of claim 2 , wherein the cancer is lymphoplasmacytic lymphoma (LPL).
19. The method of claim 2 , wherein the cancer is marginal zone lymphoma (MZL).